Jacobs Levy Equity Management
CODX

Jacobs Levy Equity Management’s Co-Diagnostics CODX Stock Holding History

Jacobs Levy Equity Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,642
Closed -$72.9K – 988
2023
Q1 		$72.9K Buy
+1,642
New +$132K ﹤0.01% 935

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Jacobs Levy Equity Management's CODX Position: Q2 2023 in Review

Jacobs Levy Equity Management sold out of Co-Diagnostics (CODX) in Q2 2023, closing a stake of 1,642 shares — an estimated $72.9K sold.

Jacobs Levy Equity Management first reported a position in CODX in Q1 2023 and held it in 1 quarter. The position peaked at $72.9K in Q1 2023. 43 funds tracked by Wall St. Rank hold CODX as of Q2 2023.

  • Jacobs Levy Equity Management reported no remaining Co-Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 1,642 Co-Diagnostics shares in Q2 2023, an estimated $72.9K.
  • Jacobs Levy Equity Management first reported a position in Co-Diagnostics in Q1 2023 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Co-Diagnostics position peaked at $72.9K in Q1 2023.
  • 43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2023, filed 14 Aug 2023.